Non Hodgkin Lymphoma Clinical Trial

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Summary

Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia, or Non-Hodgkin's Lymphoma
Refractory to or relapsed after at least 1 prior treatment regimen
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria:

Any major surgery, chemotherapy or immunotherapy within the last 21 days
Known hepatitis B virus, hepatitis C virus or HIV infection
Known histological transformation from CLL to an aggressive lymphoma (Richter's)

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

78

Study ID:

NCT03379051

Recruitment Status:

Terminated

Sponsor:

TG Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

TG Therapeutics Investigational Trial Site
Chicago Illinois, 60611, United States
TG Therapeutics Investigational Trial Site
Rochester New York, 14642, United States
TG Therapeutics Investigational Trial Site
Cleveland Ohio, 44195, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

78

Study ID:

NCT03379051

Recruitment Status:

Terminated

Sponsor:


TG Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.